PD-1/PD-L1信号通路与肿瘤  

PD-1/PD-L1 pathway and tumors

作　　者：杜国强[1] 王瑾[1] 

机构地区：[1]中国医科大学附属盛京医院耳鼻喉科,辽宁沈阳110004

出　　处：《解剖科学进展》2017年第5期525-528,共4页Progress of Anatomical Sciences

基　　金：国家自然科学基金青年基金(81202126)

摘　　要：程序性死亡因子-1(Programmed death-1,PD-1)及配体(Programmed death ligand-1,PD-L1)作为一组免疫检验点共抑制分子通过激活下游信号通路抑制T细胞的活化、增殖及细胞因子的分泌,诱导效应T细胞凋亡。肿瘤发生时,PD-1/PD-L1表达异常增加,参与肿瘤的免疫逃逸,与肿瘤浸润、转移及病人预后密切相关。抑制PD-1/PD-L1信号通路可逆转T细胞抗肿瘤效应。Programmed death-l（PD-1）/programmed death ligand-l（PD-L1） axis belongs to immunosuppressive pathway. PD-1 binds with PD-L1 can activate downstream signaling pathways and inhibit T cell activation, cell prdiferation and the secretion of cytokines, lead ing to the shut-off of T cell activation. Usually, PD-1/PD-L1 was overexpressed abnormally when the tumor happens, play a very pivotal role in tumor escape host immune responses, and assoeiated with the tumor＇s invasion, metastasis and prognosis of patients. Blocking PD-1/PD-L1 pathway can reverse the effect of T-cell antitumor.

关 键 词：信号通路 肿瘤发生 death-1 T细胞凋亡 共抑制分子 抗肿瘤效应 死亡因子 免疫检验 

分 类 号：R730.2[医药卫生—肿瘤]